BREATHE-Xchange

Welcome to
BREATHE-Xchange

Join us for a series of Webcasts discussing strategies for the optimal management of COPD with some of today's leading respiratory opinion leaders!

more info

Register today to view the archived programs


Improving Outcomes in COPD:
An Evidence-Based Approach to Disease Management

Antonio R. Anzueto, MD


Optimizing Patient Care in COPD:
A Case-Based Perspective

Sanjay Sethi, MD


Redefining the Standard of Care in COPD:
What is the Role of Nebulization?

Donald P. Tashkin, MD

Indications

Perforomist® (formoterol fumarate) Inhalation Solution is a long-acting beta2-agonist indicated for long-term, twice-daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with COPD, including chronic bronchitis and emphysema.

Important Safety Information

There is an increased risk of asthma-related death with long-acting beta2-agonists, the class of drugs to which Perforomist® Inhalation Solution belongs. Perforomist® Inhalation Solution is not indicated for asthma or in deteriorating COPD. Perforomist® Inhalation Solution should not be used to treat acute symptoms, which should be treated with an inhaled short-acting beta2-agonist.

Click here for full prescribing information for Perforomist® Solution, including boxed warning.

Click here for additional important safety information.

Spiriva® HandiHaler® is indicated for the long-term, once-daily maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema.

Spiriva® HandiHaler® is not indicated for the initial treatment of acute episodes of bronchospasm; ie, rescue therapy.

Perforomist® is a registered trademark of Dey, L.P.
U.S. Patent Nos. 6,814,953 and 6,667,344
DEY® is a registered trademark of Dey, L.P.
© 2009 Dey, L.P. All rights reserved.

Spiriva® and HandiHaler® are registered trademarks and are used under license from Boehringer Ingelheim GmbH.